New pharmacological approaches for the treatment of alcoholism

Expert Opinion on Pharmacotherapy

Volumn 7, Issue 17, 2006, Pages 2341-2353

  Soyka, Michael ^a,b   Roesner, Susanne ^a,c  

^a UNIVERSITY OF MUNICH   (Germany)

^b Private Hospital Meiringen   (Switzerland)

^c Institute for Therapy Research   (Germany)

Author keywords

Acamprosate; Alcoholism; Disulfiram; Naltrexone; Topiramate

Indexed keywords

ACAMPROSATE; ALCOHOL; ANTICONVULSIVE AGENT; ANTIDEPRESSANT AGENT; ATYPICAL ANTIPSYCHOTIC AGENT; BUSPIRONE; CARBAMAZEPINE; CLOZAPINE; DISULFIRAM; LITHIUM SALT; NALMEFENE; NALTREXONE; NEUROLEPTIC AGENT; NONSTEROID ANTIINFLAMMATORY AGENT; ONDANSETRON; OPIATE ANTAGONIST; PAROXETINE; PLACEBO; RIMONABANT; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TOPIRAMATE; TRICYCLIC ANTIDEPRESSANT AGENT; VALPROIC ACID;

ALCOHOL ABSTINENCE; ALCOHOLISM; ANXIETY DISORDER; BEHAVIOR THERAPY; CLINICAL TRIAL; COGNITIVE THERAPY; COMBINATION CHEMOTHERAPY; COMORBIDITY; DIARRHEA; DRUG ABSORPTION; DRUG ALCOHOL INTERACTION; DRUG ANTAGONISM; DRUG APPROVAL; DRUG BIOAVAILABILITY; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FORMULATION; DRUG IMPLANT; EUROPE; EVIDENCE BASED MEDICINE; FOOD DRUG INTERACTION; HUMAN; LIVER TOXICITY; META ANALYSIS; MONOTHERAPY; MOOD DISORDER; NEUROTRANSMITTER RELEASE; NONHUMAN; PATIENT COMPLIANCE; PSYCHOSOCIAL CARE; PSYCHOTHERAPY; RECOMMENDED DRUG DOSE; RELAPSE; REVIEW; SCHIZOPHRENIA; SEDATION; SEIZURE; SIDE EFFECT; SYNCOPE; SYSTEMATIC REVIEW; TARDIVE DYSKINESIA; UNITED STATES; WITHDRAWAL SEIZURE;

ALCOHOL DETERRENTS; ALCOHOLISM; ANIMALS; CARBAMAZEPINE; DEPRESSION; DISEASE MODELS, ANIMAL; DISULFIRAM; EXPERT TESTIMONY; FRUCTOSE; HUMANS; NALTREXONE; RECURRENCE; TAURINE;

EID: 33751572845     PISSN: 14656566     EISSN: None     Source Type: Journal    
DOI: 10.1517/14656566.7.17.2341     Document Type: Review

References (119)

1. GRANT BF, STINSON FS, DAWSON DA, CHOU SP, RUAN WJ, PICKERING RP: Co-occurrence of 12-month alcohol and drug use disorders in the United States (2004). Results from the National Epidemiological Survey on Alcohol and Related Conditions. Arch. Gen. Psychiatry (2004) 61:361-368.
2. BUEHRINGER C, AUGUSTIN R, BERGMANN E et al.: Alcohol consumption and alcohol-related problems in Germany. Hogref & Huber Publishers, Seattle, Toronto (2002).
3. JOHNSON BA, AIT-DAOUD N: Neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Psychopharmacolagy (2000) 149:327-344.
4. DICK DM, EDENBERG HJ, XIAOLING X et al.: Association of GABRG3 with alcohol dependence. Alcohol Clin. Exp. Res. (2004) 28:4-9.
5. EDENBERG HJ, DICK DM, XUEI X et al.: Variations in GABRA 2, encoding the α2 subunit of the GABA (A) receptor, are associated with alcohol dependence and with brain oscillations. Am. J. Genet. (2004) 74:705-714.
6. BERGLUND M, THELANDER S, JONSSON E: Treating Alcohol and Drug Abuse. An Evidence Based Review. Wiley-VCH, Weinheim, Germany (2003).
7. SCHUMANN G, SPANAGEL R, MANN K: Candidate genes for alcohol dependence: animal studies. Alcohol. Clin. Exp. Res. (2003) 27:880-888.
8. BOTTLENDER M, KÖHLER J, SOYKA M: Effektivität psychosozialer Behandlungsmethoden zur medizinischen rehabilitation alkoholabhängiger patienten. Fortschr. Neurol. Psychiat. (2006) 74:19-31.
9. MILLER WR, HESTER RK: Effectiveness of alcoholism treatment: what research reveals. In: Treating Addictive Disorders: Processes of Change. WR Miller, N Heather (Eds). Plenum Press, New York, NY (1986).
10. HOLDER HD, LONGABAUGH R, MILLER WR, RUBONIS AV: Cost effectiveness of treatment for alcoholism: a first approximation. J. Stud. Alcohol. (1991) 52:517-540.
11. FULLER RK, BRANCHEY L, BRIGHTWELL DR et al.: Disulfiram treatment of alcoholism. A Veterans Administration cooperative study. JAMA (1986) 256(11):1449-1455.
12. AZRIN NH, SISSONS RW, MEYER RJ et al.: Alcoholism treatment by disulfiram and community reinforcement therapy. J. Behav. Ther. Exp. Psychiat. (1982) 13:105-112.
13. CHICK J, COUGH K, FALKOWSKI W et al.: Disulfiram treatment of alcoholism. Br. J. Psychiatry (1992) 161:84-89.
14. CARROLL KM, NICH C, BALL SA, MCCANCE E, ROUNSAVILE BJ: Treatment of cocaine and alcohol dependence with psychotherapy and disulfiram. Addiction (1998) 93(5):713-727.
15. FULLER RK, ROTH HP: Disulfiram for the treatment of alcoholism. An evaluation in 128 men. Ann. Intern. Med. (1979) 90(6):901-904.
16. GERREIN JR, ROSENBERG CM, MANOHAR V: Disulfiram maintenance in outpatient treatment of alcoholism. Arch. Gen. Psychiatry, (1973) 28(6):798-802.
17. KEANE TM, FOY DW, NUNN B, RYCHTARIK RG: Spouse contracting to increase antabuse compliance in alcoholic veterans. J. Clin. Psychol. (1984) 40(1):340-344.
18. MILLER WR: Effectiveness of the community reinforcement approach: final progress report to the National Institute on Alcohol Abuse and Alcoholism. University of New Mexico, Center of Alcoholism, Substance Abuse and Addictions. Albuquerque, NM (1992).
19. HUGHES C, COOK CCH: The efficacy of disulfiram: a review of outcome studies. Addiction (1997) 92:381-395.
20. GARBUTT JC, WEST SL, CAREY TS, LOHR KN, CREWS FT: Pharmacological treatment of alcohol dependence. A review of the evidence. JAMA (1999) 281:1318-1325.
21. BREWER C, MEYERS RJ, JOHNSEN J: Does disulfiram help to prevent relapse in alcohol abuse? CNS Drugs (2000) 5:329-341.
22. JOHNSEN J, MORLAND J: Disulfiram implant: a double-blind placebo controlled follow-up on treatment outcome. Alcohol. Clin. Exp. Res. (1991) 15:532-536.
23. LITTLETON J: Acamprosate in alcohol dependence: how does it work? Addiction (1995) 90:1179-1188.
24. SPANAGEL R, ZIEGLGANSBERGER W: Anti-craving compounds for ethanol: new pharmacological tools to study addictive processes. Trends Pharmacol. Sci. (1997) 18:54-59.
25. SPANAGEL R, PENDYALA G, ABARCA C et al.: The clock gene Per2 influences the glutama-tergic system and modulates alcohol consumption. Nat. Med. (2005) 11(2):23-24.
26. CANO-CEBRIAN MJ et al.: Effects of acamprosate blocks the increase of dopamine extracellular levels in nucleus accumbens evoked by chemical stimulation of the ventral hippocampus. Naunyn-Schmiedebergs Arch. Pharm. (2003) 368:324-327.
27. SPANAGEL R, WEISS F: The dopamine hypothesis of reward: past and current status. Trends Neurosci. (1999) 22:521-527.
28. BALTIERI DA, DE ANDRADE AG: Efficacy of acamprosate in the treatment of alcohol-dependent outpatients. Revista Brasileira de Psiquiatria (2003) 25(3):156-159.
29. BARRIAS JA, CHABAC S, FERREIRA L, FONTE A, POTGIETER AS: Acamprosate: multicenter Portuguese efficacy and tolerance evaluation study. Psyquiatria Clinica, (1997) 18:149-160.
30. BESSON J, AEBY F, KASAS A, LEHERT P, POTGIETER A: Combined efficacy of acamprosate and disulfiram in the treatment of alcoholism: a controlled study. Alcohol. Clin. Exp. Res. (1998) 22(3):573-579.
31. CHICK J, HOWLETT H, MORGAN MY, RITSON B: United Kingdom Multicentre Acamprosate Study (UKMAS): a 6-month prospective study of acamprosate versus placebo in preventing relapse after withdrawal from alcohol. Alcohol Alcohol. (2000) 35(2):176-187.
32. GEERLINGS PJ, ANSOMS C, VAN DEN BRINK W: Acamprosate and prevention of relapse in alcoholics. Results of a randomized, placebo-controlled, double-blind study in out-patient alcoholics in The Netherlands, Belgium and Luxembourg. European Addiction Research (1997) 3:129-137.
33. GUAL A, LEHERT P: Acamprosate during and after acute alcohol withdrawal: a double-blind placebo-controlled study in Spain. Alcohol Alcohol. (2001) 36(5):413-418.
34. KIEFER F, JAHN H, TARNASKE T et al.: Comparing and combining naltrexone and acamprosate in relapse prevention of alcoholism: a double-blind, placebo-controlled study. Arch. Gen. Psychiatry (2003) 60:92-99.
35. LADEWIG D, KNECT T, LEHER P, FENDL A: Acamprosate - a stabalizing factor in long-term withdrawal of alcoholic patinets. Ther. Umschau (1993) 50:182-188.
36. LHUINTRE J, DAOUST M, MOORE ND et al.: Ability of calcium bis acetyl homotaurine, a GABA agonist, to prevent relapse in weaned alcoholics. Lancer (1985) 1(4):1014-1016.
37. LADURE P, LIBERT C, BOISMARE F, HILLEMAND B: Acamprosate appears to decrease alcohol intake in weaned alcoholics. Alcohol Alcohol. (1990) 25:613-622.
38. MASON BJ, GOODMAN AM, CHABAC S, LEHERT P: Effect of oral acamprosate on abstinence in patients with alcohol dependence in a double-blind, placebo-controlled trial: the role of patient motivation. J. Psychiatry Res. (2006) 40:383-303.
39. NAMKOONG K, LEE BO, LEE PG, CHOI MJ, LEE E, INVESTIGATORS: Acamprosate in Korean alcohol-dependent patients: a multi-centre, randomized, double-blind, placebo-controlled study. Alcohol Alcohol. (2003) 38(2):135-141.
40. NIEDERHOFER H, STAFFEN W: Acamprosate and its efficacy in treating alcohol dependent adolescents. European Child and Adolesc. Psychiatry (2003) 12(3):144-148.
41. PAILLE FM, GUELFI JD, PERKINS AC, ROYER RJ, STERU L, PAROT P: Double-blind randomized multicentre trial of acamprosate in maintaining abstinence from alcohol. Alcohol Alcohol. (1995) 30(2):239-247.
42. PELC I, LE BON O, LEHERT P, VERBANCK P: Acamprosate in the treatment of alcohol dependence: a six month postdetoxification study. In: Acamprosate in Relapse Prevention of Alcoholism. M Soyka (Ed.), Springer-Verlag, Berlin (1992):133-142.
43. PELC I, VERBANCK P, LE BON O, GAVRILOVIC M, LION K, LEHERT P: Efficacy and safety of acamprosate in the treatment of detoxified alcohol-dependent patients. A 90-day placebo-controlled dose-finding study. Br. J. Psychiatry (1997) 171:73-77.
44. POLDRUGO F: Acamprosate treatment in a long-term community-based alcohol rehabilitation programme. Addiction (1997) 92:1537-1546.
45. ROUSSEAUX JP, HERS D, FERAUGE M: Does acamprosate influence alcohol consumption of weaned alcoholics? J. Pharm. Belg. (1996) 51:65-68.
46. SASS H, SOYKA M, MANN K, ZIEGLGÄNSBERGER W: Relapse prevention by acamprosate. Results from a placebo-controlled study on alcohol dependence. Arch. Gen. Psychiatry (1996) 53:673-680.
47. TEMPESTA E, JANIRI L, BIGNAMINI A, CHABAC S, POTGIETER A: Acamprosate and relapse prevention in the treatment of alcohol dependence: a placebo-controlled study. Alcohol Alcohol. (2000) 35:202-209.
48. WHITWORTH AB, FISCHER F, LESCH OM et al.: Comparison of acamprosate and placebo in long-term treatment of alcohol dependence. Lancet (1996) 25(347):1438-1442.
49. MORLEY, KC, TEESSON M et al.: Naltrexone versus acamprosate in the treatment of alcohol dependence: a multi-centre, randomized, double-blind, placebo-controlled trial. Addiction (2006) 101(10):1451-1462.
50. ANTON RF, O'MALLEY SS, CIRAULO DA et al.: Combined pharmacotherapies and behavioural interventions for alcohol dependence: the Combine study: a randomized controlled trial. JAMA (2006) 295:2003-2017.
51. KRANZLER HR, VAN KIRK J: Efficacy of naltrexone and acamprosate for alcoholism treatment: a meta-analysis. Alcohol. Clin. Exp. Res. (2001) 25:1335-1341.
52. MANN K, LEHERT P, MORGAN MY: The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol. Clin. Exp. Res. (2004) 28:3332-3337.
53. KRANZLER HR: Evidence-based treatments for alcohol dependence: new results and new questions. JAMA (2006) 295:2003-2017.
54. BOUZA C, MAGRO A, MUNOZ A et al.: Efficacy and safety of naltrexone and acamprosate in the treatment of alcohol dependence: a systematic review. Addiction (2004) 99:811-828.
55. FRÖHLICH JC, LI TK: Opioid involvement in alcohol drinking. Ann. NY Acad Sci. (1994) 739:156-167.
56. O'MALLEY SS, JAFFE AJ, CHANG G et al.: Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch. Gen. Psychiatry (1992) 49:894-898.
57. O'MALLEY SS, JAFFE AJ, CHANG G et al.: Six-month follow-up of naltrexone and psychotherapy for alcohol dependence. Arch. Gen. Psychiatry (1996) 53:217-224.
58. VOLPICELLI J, ALTERMAN AI, HAYASHIDA M, O'BRIEN CP, O'BRIEN C: Naltrexone in the treatment of alcohol dependence. Arch. Gen. Psychiatry (1992) 49(11):876-880.
59. VOLPICELLI J, WATSON NT, KING AC, SHERMAN CE, O'BRIEN CP: Effect of naltrexone on alcohol 'high' in alcoholics. Am. J. Psychiatry (1995) 152(4):613-615.
60. ANTON RF, MOAK DH, LATHAM PK et al.: Posttreatment results of combining naltrexone and cognitive-behavior therapy 6,r the treatment of alcoholism. J. Clin. Psychopharmacol. (2000) 21:72-77.
61. GASTPAR M, BONNET U, BONING J et al.: Lack of efficacy of naltrexone in the prevention of alcohol relapse:results from a german multicenter study. J. Clin. Psychopharmacol. (2002) 22(6):592-598.
62. ANTON RF, MOAK DH, WAID LR, LATHAM PK, MALCOLM RJ, DIAS JK: Naltrexone and cognitive behavioral therapy for the treatment of outpatient alcoholics: Results of a placebo-controlled trial. Am. J. Psychiatry (1999) 156(11):1758-1764.
63. BALLDIN J, BERGLUND M, BORG S et al.: A 6-month controlled naltrexone study: Combined effect with cognitive behavioral therapy in outpatient treatment of alcohol dependence. Alcohol. Clin. Exp. Res. (2003) 27(7):1142-1149.
64. CHICK J, ANTON R, CHECINSKI K et al.: A multicentre, randomized, double-blind, placebo-controlled trial of naltrexone in the treatment of alcohol dependence or abuse. Alcohol Alcohol. (2000) 35(6):587-593.
65. GUARDIA J, CASO C, ARIAS F et al.: A double-blind, placebo controlled study of naltrexone in the treatment of alcohol dependence disorder: results from a multicenter clinical trial. Alcohol Clin. Exp. Res. (2002) 26(9):1381-1387.
66. HEINALA P, ALHO H, KIIANMAA K, LONNQVIST J, KUOPPASALMI K, SINCLAIR JD: Targeted use of naltrexone without prior detoxification in the treatment of alcohol dependence: a factorial double-blind, placebo-controlled trial. J. Clin. Psychopharmacol. (2001) 21(3):287-292.
67. HERSH D, VAN KIRK JR, KRANZLER HR: Naltrexone treatment of comorbid alcohol and cocaine use disorders. Psychopharmacology (1998) 139(1):44-52.
68. KILLEEN TK, BRADY KT, GOLD PB et al.: Effectiveness of naltrexone in a community treatment program.Alcohol. Clin. Exp. Ret. (2004) 28(11):1710-1717.
69. KRANZLER HR, MODESTO-LOWE V, VAN KIRK J: Naltrexone versus nefazodone for treatment of alcohol dependence. A placebo-controlled trial. Neuropsychopharmacology (2000) 22(5):493-503.
70. KRYSTAL JH, JOYCE A, CRAMER BS et al.: Naltrexone in the treatment of alcohol dependence. New Engl. J. Med. (2001) 345(24):1734-1739.
71. LATT NC, JURD S, HOUSEMAN J, WUTZKE SE: Naltrexone in alcohol dependence: a randomised controlled trial of effectiveness in a standard clinical setting. Med. J. Aust. (2002) 176(11):530-534.
72. LEE A, TAN S, LIM D et al.: Naltrexone in the treatment of alcoholism - an effectiveness study in Singapore. Drug Alcohol Rev. (2001) 20:193-199.
73. MONTI PM, ROHSENOW DJ, SWIFT RM et al.: Naltrexone and cue exposure with coping and communication skills training for alcoholics: treatment process and 1-year outcomes. Alcohol. Clin. Exp. Res. (2001) 25(11):1634-1647.
74. MORRIS PL, HOPWOOD M, WHELAN G, GARDINER J, DRUMMOND E: Naltrexone for alcohol dependence. Addiction (2001) 96(11):1565-1573.
75. O'MALLEY SS, ROUNSAVILLE BJ, FARREN C et al.: Initial and maintenance naltrexone treatment for alcohol dependence using primary care versus specialty care: a nested sequence of 3 randomized trials. Arch. Intern. Med. (2003) 163(14):1695-1704.
76. OSLIN D, LIBERTO JG, O'BRIEN J, KROIS S, NORBECK J: Naltrexone as an adjunctive treatment for older patients with alcohol dependence. Am. J. Geriatr. Psychiatry (1997) 5(4):324-332.
77. KRANZLER HR, WESSON DR, BILLOT L: Naltrexone depot for treatment of alcohol dependence: a multicenter, randomized, placebo-controlled clinical trial. Alcohol Clin. Exp. Res. (2004) 28:1051-1059.
78. GARBUTT JC, KRANZLER HR, O'MALLEY SS et al.: Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence. JAMA (2005) 293:1617-1625.
79. STREETON C, WHELAN G: Naltrexone, a relapse prevention maintenance treatment of alcohol dependence: a meta-analysis of 0randomized controlled trials. Alcohol Alcohol. (2001) 36:544-552.
80. SRISURAPANONT M, JARUSURAISIN N: Opioid antagonists for alcohol dependence. Cochrane Database Syst. Rev. (2002) 2:CD001867.
81. MASON BJ, SALVATO FR, WILLIAMS LD et al.: A double-blind, placebo-controlled study of oral nalmefene for alcohol dependence. Arch. Gen. Psychiatry (1999) 56:719-724.
82. ANTON RF, PETTINATI H et al.: A multi-site dose ranging study of nalmefene in the treatment of alcohol dependence. J. Clin. Psychopharmacol. (2004) 24:421-428.
83. MUELLER TI, STOUT RL, RUDDEN S, et al.: A double-blind, placebo-controlled pilot study of carbamazepine for the treatment of alcohol dependence. Alcohol. Clin. Exp. Res. (1997) 21:86-92.
84. MALCOLM R, MYRICK H, BRADY KT, BALLENGER JC: Update on anticonvulsants for the treatment of alcohol withdrawal. Am. J. Addict. (2001) 10(Suppl.): 16-23.
85. LONGO LP, CAMPBELL T, HUBATCH S: Divalproex sodium (depakote) for alcohol withdrawal and relapse prevention. J. Addict. Dis. (2002) 21:55-64.
86. BRADY KT, MYRICK H, HENDERSON S, COFFEY SF: The use of divalproex in alcohol relapse prevention: a pilot study. Drug Alcohol Depend. (2002) 67:323-330.
87. JOHNSON BA: Progress in the development of topiramate for treating alcohol dependence: from a hypothesis to a proof-of-concept study. Alcohol. Clin. Exp. Rex. (2004) 28:1137-1144.
88. JOHNSON BA, AIT-DAOUD N, BOWDEN CL et al.: Oral topiramate for treatment of alcohol dependence: a randomised controlled trial. Lancet (2003) 361:1677-1685.
89. SULLIVAN LE, FIELLIN DA, O'CONNOR PG: The prevalence and impact of alcohol problems in major depression: a systematic review. Am. J. Med. (2005) 118:330-341.
90. KESSLER RC, CRUM RM, WARNER LA et al.: Lifetime co-occurrence of DSM-III-R alcohol abuse and dependence with other psychiatric disorders in the National Comorbidity Survey. Arch. Gen. Psychiatry (1997) 54:313-321.
91. BROWN RA, EVANS DM, MILLER JBW, BURGESS ES, MUELLER TI: Cognitive-behavioral treatment for depression in alcoholism. J. Consult. Clin. Psychol. (1997) 65:715-726.
92. NUNES EV, LEVIN FR: Treatment of depression in patients with alcohol or other drug dependence. JAMA (2004) 291:1887-1896.
93. CIRAULO DA, JAFFE JH: Tricyclic antidepressants in the treatment of depression associated with alcoholism. J. Clin. Psychopharmacol. (1981) 1(3):146-150.
94. CORNELIUS JR, SALLOUM IM, EHLER JG et al.: Double-blind fluoxetine in depressed alcoholic smokers. Psychopharmacol. Bull. 33(1):165-170.
95. PETTINATI HM, VOLPICELLI JR, LUCK G et al.: Double-blind clinical trial of sertraline treatment for alcohol dependence. J. Clin. Psychopharmacol. 21(2):143-153.
96. MCGRATH PJ, NUNES EV, STEWART JW et al.: Imipramine treatment of alcoholics with primary depression: a placebo-controlled clinical trial. Arch. Gen. Psychiatry (1996) 53(3):232-240.
97. LEFAUVRE CE, LITTEN RZ, RANDALL CL, MOAK DH, DALLOUM IM, GREEN AI: Pharmacological treatment of alcohol abuse/dependence with psychiatric comorbidity. Alcohol. Clin. Exp. Res. (2004) 28:302-312.
98. SALLOUM IM, CORNELIUS JR, DALEY DC, KIRISCI L, HIMMELHOCH JM, THASE ME: Efficacy of valproat maintenance in patients with bipolar disorder and alcoholism: a double-blind placebo-controlled study. Arch. Gen. Psychiatry (2005) 62:37-45.
99. RANDALL CL, JOHNSON MR, THEVOS AK et al.: Paroxetine for social anxiety and alcohol use in dual-diagnosed patients. Depress. Anxiety (2001) 14:255-262.
100. MALEC TS, MALEC EA, DONGIER M: Efficacy of buspirone in alcohol dependence: a review. Alcohol. Clin. Exp. Res. (1996) 20:853-858.
101. SOYKA M: Alcoholism and schizophrenia (editorial). Addiction (2000) 95(11):1613-1618.
102. SOYKA M, ALBUS M, FINELLI A et al.: Prevalence of alcohol and drug abuse in schizophrenic inpatients. Eur Arch Psychiatry Clin. Neurosci. (1993) 242:362-372.
103. SOYKA M: Addiction and schizophrenia. Nosological, clinical and therapeutic questions. 1. Alcoholism and schizophrenia. Fortschr. Neurol. Psychiatr. (1995) 62:71-87.
104. GREEN AI, BURGESS ES, DAWSON R, ZIMMET SV, STROUS RD: Alcohol and cannabis use in schizophrenia: effects of clozapine and risperidone. Schizophr. Res. (2002) 60:81-85.
105. DRAKE RE, XIE H, MCHUGO GJ, GREEN AI: The effects of clozapine on alcohol and drug use disorders among patients with schizophrenia. Schizophr. Bull. (2000) 26:441-449.
106. GREEN AI: Schizophrenia and comorbid substance use disorder. Effects of antipsychotics. J. Clin. Psychiatry (2005) 66(Suppl. 6):21-26.
107. NOORDSY DL, O'KEEFE C, MUESER KT, XIE H: Six month outcomes for patients who switched to olanzapine treatment. Psychiatry Serv. (2001) 52: 501-507.
108. SOYKA M: Dual diagnosis in patients with schizophrenia: issues in pharmacological treatment. CNS Drugs (1996) 6:414-425.
109. WILKINS JN: Pharmacotherapy of schizophrenia patients with comorbid substance abuse. Schizophrenia Bull. (1997) 23:215-228.
110. MILLER DEL D, MCEVOY JP, DAVIS SM et al.: Clinical correlates of tardive dyskinesia in schizophrenia: baseline data from the CATIE schizophrenia trial. Schizophr. Res. (2005) 80:33-43.
111. CHAMBERS A, KRYSTAL J, SELF D: A neurobiological basis for substance abuse comorbidity in schizophrenia. Biol. Psychiatry (2001) 50:71-83.
112. SIRIS SG: Pharmacological treatment of substance-abusing schizophrenic patients. Schizophrenia Bull (1990) 16:111-122.
113. ECONOMIDOU D, MATTIOLI L, CIFANI C et al.: Effect of the cannabiniod cb1 receptor antagonist sr-141716a on ethanol self-administration and ethanol-seeking behaviour in rats. Psychopharmacology (2006) 183:394-403.
114. GELFAND EV, CANNON CP: Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors. Expert Opin. Investig. Drugs (2006) 15:307-315.
115. PI-SUNYER FX, ARONNE LJ, HESHMATI HM, DEVIN J, ROSENSTOCK J, RIO-NORTH AMERICA STUDY GROUP: Effect of rimonabant, a cannabinoid-1 receptor blocker, on weight and cardiometabolic risk factors in overweight or obese patients: RIO-North America: a randomized controlled trial. JAMA (2006) 295:826-828.
116. KENNA GA, MCGEARY JE, SWIFT RM: Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, Part 1. Am. J. Health Syst. Pharm. (2004) 61:2272-2279.
117. KENNA GA, MCGEARY JE, SWIFT RM: Pharmacotherapy, pharmacogenomics, and the future of alcohol dependence treatment, Part 2. Am. J. Health Syst. Pharm. (2004) 61:2380-2388.
118. COHEN E, FEINN R, ARIAS A, KRANZLER HR: Alcohol treatment utilization: findings from the national epidemiologic survey on alcohol and related conditions. Drug Alcohol Depend. (2006) In press.
119. BÜHRINGER G, KRÖGER C, KÜFNER H et al.: Substance abuse network ASAT: Allocating Substance Treatments to patient heterogeneity (in German). Suchtmed. (2004) 6:7-13.